ABBOTINDIA.NSE

Abbott India Ltd.

… Patwari, CHRO, Alembic Pharmaceuticals Limited; Dr. … Abbott India * Alembic Pharmaceuticals Ltd. * Apollo Hospitals … Enterprise Limited * CADILA PHARMACEUTICALS LIMITED * Dr. Reddy… Dhirubhai Ambani Hospital * Matrix Pharmacorp * Medtronic * P. D …

Indian equity benchmarks inched lower on Tuesday as a drop in financials weighed ahead of key U.S. and domestic inflation readings. The Nifty 50 fell 0.4% to 24,487.4 points and the BSE Sensex shed 0.46% to 80,235.59. Investors await U.S. CPI data due later in the day which will guide the Federal Reserve’s rate-cut path. Lower U.S. rates typically boost the appeal of emerging market equities, including India, as yields on U.S. Treasuries fall. Eight of the 16 major sectors logged gains. The broader small-caps were flat, while mid-caps slipped 0.3%. Financials, which gained 0.9% in the previous session, reversed course and fell 1% on Tuesday. IT rose 0.4%, on the back of a U.S.-China tariff truce extension that averts triple-digit duties that is expected to shield U.S. growth, curb inflation risks, and support corporate discretionary spending, including on technology. Pharma advanced 0.7%, buoyed by strong results from Abbott India and Alkem Laboratories. The sector, like IT, counts the U.S. as a key market.

Indian equity benchmarks inched lower on Tuesday as a drop in financials weighed ahead of key U.S. and domestic inflation readings. The Nifty 50 fell 0.4% to 24,487.4 points and the BSE Sensex shed 0.46% to 80,235.59. Investors await U.S. CPI data due later in the day which will guide the Federal Reserve’s rate-cut path. Lower U.S. rates typically boost the appeal of emerging market equities, including India, as yields on U.S. Treasuries fall. Eight of the 16 major sectors logged gains. The broader small-caps were flat, while mid-caps slipped 0.3%. Financials, which gained 0.9% in the previous session, reversed course and fell 1% on Tuesday. IT rose 0.4%, on the back of a U.S.-China tariff truce extension that averts triple-digit duties that is expected to shield U.S. growth, curb inflation risks, and support corporate discretionary spending, including on technology. Pharma advanced 0.7%, buoyed by strong results from Abbott India and Alkem Laboratories. The sector, like IT, counts the U.S. as a key market.

Q1 earnings delivered a mixed bag, with HAL signalling a recovery, Alkem and Abbott maintaining steady growth, and Balrampur Chini facing near-term pressures

… ’s healthcare brands from the pharmaceutical division of Bayer in India … the fourth from multinational corporations. Sanofi, GlaxoSmithKline and Abbott India were the …

… ’s healthcare brands from the pharmaceutical division of Bayer in India … the fourth from multinational corporations. Sanofi, GlaxoSmithKline and Abbott India were the …

India's pharmaceutical sector faced a 6% decline in the Nifty Pharma index in 2025, while the Nifty 50 index rose 8%. Major firms experienced significant losses, though some companies like Laurus Labs and Abbott India saw gains amid investor concerns over tariffs and macroeconomic issues.

India's pharmaceutical sector faced a 6% decline in the Nifty Pharma index in 2025, while the Nifty 50 index rose 8%. Major firms experienced significant losses, though some companies like Laurus Labs and Abbott India saw gains amid investor concerns over tariffs and macroeconomic issues.

Indian markets extended gains for the third straight session on Thursday, with the Sensex rising over 1,000 points and Nifty50 closing above 25,500. Sectoral gains were led by energy, utilities, oil & gas, and metals, while IT and realty stocks saw some profit booking. Several breakout stocks, including Nuvama Wealth, Abbott India, and Max Healthcare, hit fresh 52-week highs.